Full Press Release Details
japan first in the world to approve dupixent dupilumab for chronic spontaneous urticaria csu.
REGN
japan first in the world to approve dupixent dupilumab for chronic spontaneous urticaria csu
Key Takeaway: japan first in the world to approve dupixent dupilumab for chronic spontaneous urticaria csu